AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing

AbbVie delivered strong Q1 2026 results, with revenue of $15B, up 12.4% year over year, and Skyrizi sales rising 30.9%, leading management to raise EPS guidance. Despite concerns about new oral competitors such as Icotyde, Skyrizi's efficacy advantage and expanding indications support continued growth. The stock is valued at 14.2x 2026 EPS and a 0.84x PEG, with a $250/share price target versus 17% projected earnings growth.

Analysis

ABBV’s setup is less about one quarter and more about the durability of a multiple re-rate: the market is still valuing this like a mature pharma with patent-cycle risk, while the growth engine is behaving like a high-quality specialty franchise. The key second-order effect is on competitors’ commercial budgets and pipeline economics — if Skyrizi continues taking share while expanding into new indications, rival immunology launches likely face a worse ROI on salesforce spend, payer contracting, and DTC messaging, which can compress category growth across the field.

The near-term bull case is that earnings revisions should continue upward for the next 2-3 quarters, and that matters more than headline EPS beats because valuation is still anchored below the broader large-cap healthcare growth cohort. The main watch item is whether management converts this into sustained guidance discipline: if the street starts modeling a multi-year mid-teens EPS comp, the stock can absorb a meaningfully higher multiple without needing a perfect macro tape.

The contrarian angle is that consensus may be underestimating competitive inertia, not because the oral entrants are better, but because payers are increasingly willing to trial cheaper convenience-driven options before granting broad access. That creates a slower-burn risk over 6-18 months: not share loss all at once, but incremental formulary friction, longer sales cycles, and higher rebate intensity that can quietly erode operating leverage. The market is likely also underpricing how much of ABBV’s current valuation already reflects good news; if the next data read is merely good rather than better, upside may come from multiple stability more than further expansion.

Key Decisions for Investors

• Go long ABBV on a 3-6 month horizon on any post-earnings consolidation; target a 15-20% upside if estimates keep moving higher and the multiple re-rates toward high-quality large-cap healthcare peers.
• Use a bull call spread in ABBV for the next 2 quarters to express upside with defined risk; attractive if implied vol stays elevated relative to realized earnings drift.
• Pair trade: long ABBV / short a basket of immunology or oral-convenience competitors most exposed to payer switching pressure; the trade works if market share remains sticky and rebate dynamics intensify.
• Trim or hedge if the stock approaches the $250 target before the next catalyst cycle; at that point the risk/reward shifts from revision-driven upside to execution-dependent defense.
• For longer-dated exposure, add on weakness only after confirming that new indication momentum is translating into payer access rather than just headline prescribing growth.